EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas

Aristeidis G Vaiopoulos iD, Maria Dalamaga, Pelagia Katsimbri, Marios Koumourtzis, Kyriaki Lampadaki, Konstantinos Theodoropoulos, Sofia Theotokoglou, Antonios Kanelleas iD, Anna Syrmali, Alexandra Filippopoulou, Konstantina Zoupidou, Alexander Katoulis iD und 1 weitere

International Journal of Dermatology · 2023

DOI: 10.1111/ijd.16849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2023. Verfasst von Aristeidis G Vaiopoulos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Dermatology and Venereology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of At…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antibodies, Monoclonal, Humanized, Interleukin-23, Psoriasis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis and psoriatic arthritis are chronic inflammatory skin and joint diseases requiring effective therapies. Although clinical studies have shown the efficacy of IL‐23 inhibitors, real‐world data are limited.

Methods

We conducted a single‐center retrospective Greek study enrolling patients with psoriatic arthritis and moderate‐to‐severe plaque psoriasis being treated at our multidisciplinary psoriasis outpatient clinic. Our aim was to investigate the efficacy and safety of IL‐23 inhibitors guselkumab and risankizumab. Additionally, we sought to determine the clinical characteristics affecting treatment response. Primary endpoints were the evaluation of absolute Psoriasis Area and Severity Index (aPASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) at week 24.

Results

Fifty‐nine patients (55.9% male, 69.5% early onset) with a mean age of 51.7 years were included. Twenty‐four patients (40.7%) had a concomitant psoriatic arthritis. Obesity was the main comorbidity (49.2%) with a mean body mass index (BMI) of 31.3 kg/m 2 . Additional comorbidities were hypertension (44.1%), dyslipidemia (32.2%), and diabetes (18.6%). Only eight patients (13.6%) were naïve to previous systemic treatments, whereas 40 patients (67.8%) were bio‐experienced. A statistically significant improvement of aPASI and DAPSA was demonstrated after 4, 16, and 24 weeks of treatment ( P < 0.05). IL23 blockers were also efficacious in difficult‐to‐treat areas. Clinical outcome was affected from previous treatment with biologics. Treatment response was the same between guselkumab and risankizumab ( P > 0.05).

Conclusion

This real‐world study confirms the efficacy and safety of guselkumab and risankizumab in psoriatic arthritis and psoriasis reported from clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticAntibodies, Monoclonal, HumanizedInterleukin-23PsoriasisHumansMaleFemaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAdultAgedAntibodies, Monoclonal

Substanzen

guselkumabrisankizumabAntibodies, Monoclonal, HumanizedInterleukin-23Antibodies, Monoclonal

Autor:innen und Institutionen

  • Second Department of Dermatology and Venereology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Biologic Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.

ORCID-Profile: Aristeidis G Vaiopoulos, Antonios Kanelleas, Alexander Katoulis

Zitieren

APA

Vaiopoulos, A. G., Dalamaga, M., Katsimbri, P., Koumourtzis, M., Lampadaki, K., Theodoropoulos, K., Theotokoglou, S., Kanelleas, A., Syrmali, A., Filippopoulou, A., Zoupidou, K., Katoulis, A., & Papadavid, E. (2023). Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas. International Journal of Dermatology. https://doi.org/10.1111/ijd.16849

Vancouver

Vaiopoulos AG, Dalamaga M, Katsimbri P, Koumourtzis M, Lampadaki K, Theodoropoulos K, et al. Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas. International Journal of Dermatology. 2023. doi:10.1111/ijd.16849

BibTeX
@article{Vaiopoulos2023,
  author = {Vaiopoulos, Aristeidis G and Dalamaga, Maria and Katsimbri, Pelagia and Koumourtzis, Marios and Lampadaki, Kyriaki and Theodoropoulos, Konstantinos and Theotokoglou, Sofia and Kanelleas, Antonios and Syrmali, Anna and Filippopoulou, Alexandra and Zoupidou, Konstantina and Katoulis, Alexander and Papadavid, Evangelia},
  title = {Real‐world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas},
  journal = {International Journal of Dermatology},
  year = {2023},
  doi = {10.1111/ijd.16849}
}
Kostenlos starten →